130 related articles for article (PubMed ID: 29465505)
21. High frequency of BRAF mutations in primary mucinous ovarian carcinoma of Taiwanese patients.
Chao WR; Lee YJ; Lee MY; Sheu GT; Han CP
Taiwan J Obstet Gynecol; 2021 Nov; 60(6):1072-1077. PubMed ID: 34794740
[TBL] [Abstract][Full Text] [Related]
22. Both
Koo CL; Lee MY; Chao WR; Han CP
J Cancer Res Ther; 2022; 18(3):862-863. PubMed ID: 35900578
[No Abstract] [Full Text] [Related]
23. The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma.
Chang KL; Lee MY; Chao WR; Han CP
Hum Genomics; 2016 Dec; 10(1):40. PubMed ID: 28031051
[TBL] [Abstract][Full Text] [Related]
24. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
[TBL] [Abstract][Full Text] [Related]
25. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
26. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
[TBL] [Abstract][Full Text] [Related]
27. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.
Gemignani ML; Schlaerth AC; Bogomolniy F; Barakat RR; Lin O; Soslow R; Venkatraman E; Boyd J
Gynecol Oncol; 2003 Aug; 90(2):378-81. PubMed ID: 12893203
[TBL] [Abstract][Full Text] [Related]
28. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
29. Molecular characterization of 103 ovarian serous and mucinous tumors.
Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
[TBL] [Abstract][Full Text] [Related]
30. [Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas].
Gao J; Zhang J; Lu T; Li XY; Jia N; Liang ZY
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):595-8. PubMed ID: 23157826
[TBL] [Abstract][Full Text] [Related]
31. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
Sun Y; Ren Y; Fang Z; Li C; Fang R; Gao B; Han X; Tian W; Pao W; Chen H; Ji H
J Clin Oncol; 2010 Oct; 28(30):4616-20. PubMed ID: 20855837
[TBL] [Abstract][Full Text] [Related]
32. Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary.
Xu Y; Bi R; Xiao Y; Tu X; Li M; Li A; Shan L; Zhou S; Yang W
Diagn Pathol; 2017 Dec; 12(1):87. PubMed ID: 29273082
[TBL] [Abstract][Full Text] [Related]
33. Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.
Lee YJ; Lee MY; Ruan A; Chen CK; Liu HP; Wang CJ; Chao WR; Han CP
Oncotarget; 2016 Dec; 7(50):82097-82103. PubMed ID: 27888800
[TBL] [Abstract][Full Text] [Related]
34. Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas.
Schönleben F; Allendorf JD; Qiu W; Li X; Ho DJ; Ciau NT; Fine RL; Chabot JA; Remotti HE; Su GH
Pancreas; 2008 Mar; 36(2):168-72. PubMed ID: 18376308
[TBL] [Abstract][Full Text] [Related]
35. Gene mutation profiling in Chinese colorectal cancer patients and its association with clinicopathological characteristics and prognosis.
Ye ZL; Qiu MZ; Tang T; Wang F; Zhou YX; Lei MJ; Guan WL; He CY
Cancer Med; 2020 Jan; 9(2):745-756. PubMed ID: 31782259
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice.
Shibata W; Kinoshita H; Hikiba Y; Sato T; Ishii Y; Sue S; Sugimori M; Suzuki N; Sakitani K; Ijichi H; Mori R; Endo I; Maeda S
Sci Rep; 2018 Apr; 8(1):6150. PubMed ID: 29670173
[TBL] [Abstract][Full Text] [Related]
37. Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.
Zannoni GF; Improta G; Chiarello G; Pettinato A; Petrillo M; Scollo P; Scambia G; Fraggetta F
Virchows Arch; 2014 Aug; 465(2):193-8. PubMed ID: 24889043
[TBL] [Abstract][Full Text] [Related]
38. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
39. A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix.
Hara K; Saito T; Hayashi T; Yimit A; Takahashi M; Mitani K; Takahashi M; Yao T
Pathol Res Pract; 2015 Sep; 211(9):657-64. PubMed ID: 26160192
[TBL] [Abstract][Full Text] [Related]
40. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
Gow CH; Hsieh MS; Wu SG; Shih JY
Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]